^
Association details:
Biomarker:FLT3-ITD mutation
Cancer:Acute Myelogenous Leukemia
Drug:PIN-A1 (CK1α degrader)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

2799 Anti-Leukemic Effects of CK1α Degrader As Monotherapy and in Combination with Targeted Drugs

Published date:
11/02/2023
Excerpt:
Patient-derived xenograft models from two FLT3-ITD-mutated AML patients also showed potent anti-leukemic effects of PinA1 as monotherapy and in combination with gilteritinib.